Lysogene宣布与魏茨曼科学研究所的研究合作

Lysogene宣布与魏茨曼科学研究所的研究合作150150Lysogene
  • 对于神经型戈谢病和帕亚搏全站app下载金森病GBA1突变新型AAV基因治疗方法

法国巴黎 - 2020年7月1日 - Lysogene(FR0013233475 - LYS),一期3基因治疗平台公司亚搏全站app下载针对中枢神经系统(CNS)疾病,今天宣布,该公司已与耶达研究和开发elopment有限公司,魏茨曼科学研究所的商业部门的合作研究协议。

该协议涉及Lysogene和Anthony Futerman教授在魏茨曼科学研究所实验室之间的协作,以开发用于神经型戈谢病,帕金森病,以及与GBA1基因的突变相关的其他疾病的新的AAV基因治疗方法的目的亚搏全站app下载。根据协议的条款,Lysogene将提供AAV载体的设计和生产的专业企业,同时Futerman教授的实验室将提供葡糖脑苷脂酶的提高了生物特性的变体,并进行生物证据和概念研究。Lysogene拥有独家选项许可程序。

拉尔夫·劳费尔,首席科学官Lysogene说过:“我们很高兴开始与Futerman教授,鞘脂生物学领域的顶尖专家这个研究合作。魏兹曼研究所是世界领先的多学科研究机构之一,和许多突破性的医学发现和技术应用的来源。Lysogene正在开发基因治疗方法为单基因神亚搏全站app下载经障碍,包括神经型溶酶体贮积病。这种合作是非常契合Lysogene的策略,为制定一个罕见的溶酶体疾病的一个新疗法,具有扩展到神经系统疾病有更大的患者群体,如帕金森的潜在机会。”

关于Lysogene

Lysogene是基因治疗公亚搏全站app下载司集中于中枢神经系统(CNS)的罕见疾病的治疗。公司已经建立了一个独特的功能,实现安全和有效地提供基因治疗的CNS治疗溶酶体疾病和中枢神经系统的其他遗传性疾病。A相2/3临床试验在MPS IIIA与Sarepta治疗合伙公司正在进行并且在GM1神经节苷脂的相位1/3临床试验是在制备。亚博登录首页按照Lysogene和Sarepta Therapeutics公司,Sarepta治疗之间签订的协议,公司将持有的美国和欧洲以外市场的独家商业权利LYS-SAF302;和Lysogene将保持在欧洲LYS-SAF302的商业排他性。Lysogene还与对脆性X综合征,遗传性疾病与治疗孤独症的基因治疗方法的学术合作伙伴合作。亚搏全站app下载www.astridbowlby.com。

前瞻性声明

本新闻稿可能包含某些前瞻性声明,预测和估计相对于Lysogene的临床试验,临床试验数据公布,临床开发计划,预期未来的活动和Lysogene现金跑道。Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2019 universal registration document, registered with the French Markets Authorities on April 30, 2020, under number D.20-0427, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

本新闻稿中的法语和英语编写的。在两个文本之间的差异的情况下,法语版将取代。

往来

斯特凡杜兰特DES奥尔努瓦首席财务官

stephane.durant-des-aulnois@lysogene.com

+ 33 1 41 43 03 99

Lysogene COVID-19更新

保持联系

不要犹豫,如果你需要更多的帮助与我们联系。